Literature DB >> 31453778

Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery.

Areen Alshweiat1, Rita Ambrus1, IIdikó Csoka1.   

Abstract

There is always a need for alternative and efficient methods of drug delivery. The nasal cavity can be considered as a non-invasive and efficient route of administration. It has been used for local, systemic, brain targeting, and vaccination delivery. Although, many intranasal products are currently available on the market, the majority is used for local delivery with fewer products available for the other targets. As nanotechnology utilization in the drug delivery has rapidly spread out, the nasal delivery has become attractive as a promising approach. Nanoparticulate systems facilitate drug transportation across the mucosal barrier, protect the drug from nasal enzyme degradation, enhance the delivery of vaccines to the lymphoid tissue of the nasal cavity with an adjuvant activity, and offer a way for peptide delivery into the brain and the systemic circulation, in addition to their potential for brain tumor treatment. This review article aims at discussing the potential benefit of the intranasal nanoparticulate systems, including nanosuspensions, lipid and surfactant, and polymer-based nanoparticles as regards productive intranasal delivery. The aim of this review is to focus on the topicalities of nanotechnology applications for intranasal delivery of local, systemic, brain, and vaccination purposes during the last decade, referring to the factors affecting delivery, regulatory aspects, and patient expectations. This review further identifies the benefits of applying the Quality by Design approaches (QbD) in product development. According to the reported studies on nanotechnology-based intranasal delivery, potential attention has been focused on brain targeting and vaccine delivery with promising outcomes. Despite the significant research effort in this field, nanoparticle-based products for intranasal delivery are not available. Thus, further efforts are required to promote the introduction of intranasal nanoparticulate products that can meet the requirements of regulatory affairs with high patient acceptance. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Intranasal; Quality by Design; drug delivery; nanoparticulate system; patients` expectations.zzm321990; regulatory

Year:  2019        PMID: 31453778     DOI: 10.2174/0929867326666190827151741

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  15 in total

1.  Characterization and Systemic Delivery of Dibenzoylmethane via the Intranasal Route.

Authors:  Deepal Vora; Anthony E Kincaid; Justin Tolman; Harsh Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

2.  Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia.

Authors:  Zaki F Aref; Shamardan Ezz Eldin S Bazeed; Mohammed H Hassan; Abeer S Hassan; Ali A Ghweil; Mennatallah Ali Abdelrhman Sayed; Alaa Rashad; Haggagy Mansour; Aida A Abdelmaksoud
Journal:  Infect Drug Resist       Date:  2022-09-19       Impact factor: 4.177

3.  Interleukin-4 improves white matter integrity and functional recovery after murine traumatic brain injury via oligodendroglial PPARγ.

Authors:  Hongjian Pu; Xuan Zheng; Xiaoyan Jiang; Hongfeng Mu; Fei Xu; Wen Zhu; Qing Ye; Yunneng Jizhang; T Kevin Hitchens; Yejie Shi; Xiaoming Hu; Rehana K Leak; C Edward Dixon; Michael Vl Bennett; Jun Chen
Journal:  J Cereb Blood Flow Metab       Date:  2020-08-05       Impact factor: 6.200

Review 4.  Nanomedicine for Acute Brain Injuries: Insight from Decades of Cancer Nanomedicine.

Authors:  Rebecca M Kandell; Lauren E Waggoner; Ester J Kwon
Journal:  Mol Pharm       Date:  2020-06-25       Impact factor: 4.939

5.  Development of Nanoparticulate Formulations with Biomedical Applications Related to Cancer.

Authors:  Codruta Marinela Soica
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

Review 6.  Current Perspective on Nasal Delivery Systems for Chronic Rhinosinusitis.

Authors:  Junhu Tai; Kijeong Lee; Tae Hoon Kim
Journal:  Pharmaceutics       Date:  2021-02-10       Impact factor: 6.321

7.  Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa.

Authors:  Ammar S Al Khafaji; Maureen D Donovan
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

Review 8.  Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.

Authors:  Rasha Itani; Mansour Tobaiqy; Achraf Al Faraj
Journal:  Theranostics       Date:  2020-05-01       Impact factor: 11.556

9.  Escherichia coli Heat-Labile Enterotoxin B Subunit Combined with Ginsenoside Rg1 as an Intranasal Adjuvant Triggers Type I Interferon Signaling Pathway and Enhances Adaptive Immune Responses to an Inactivated PRRSV Vaccine in ICR Mice.

Authors:  Fei Su; Yige Wu; Junxing Li; Yee Huang; Bin Yu; Lihua Xu; Yin Xue; Chenwen Xiao; Xiufang Yuan
Journal:  Vaccines (Basel)       Date:  2021-03-16

10.  Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.

Authors:  Zaki F Aref; Shamardan Ezz Eldin S Bazeed; Mohammed H Hassan; Abeer S Hassan; Alaa Rashad; Rehab G Hassan; Aida A Abdelmaksoud
Journal:  Int J Nanomedicine       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.